



## **Newron to Participate in Upcoming Investor Conferences in November and December**

**Milan, Italy - November 14, 2017** - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it will participate in the following investor conferences:

- The 29th Annual Piper Jaffray Healthcare Conference, November 29 in New York City
- Global Mizuho Investor Conference, December 4 in New York City

### **About Newron Pharmaceuticals**

Newron (SIX: NWRN) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland and the USA, and is commercialized by Newron’s Partner Zambon. US WorldMeds holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments for rare disease patients at various stages of clinical development, including sarizotan for patients with Rett syndrome and ralfinamide for patients with specific rare pain indications. Newron is also developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit. <http://www.newron.com>.

### **For more information, please contact**

#### **Newron**

Stefan Weber – CEO  
+39 02 6103 46 26  
[pr@newron.com](mailto:pr@newron.com)

#### **UK/Europe**

Julia Phillips, FTI Consulting  
+44 20 3727 1000  
[julia.phillips@FTIConsulting.com](mailto:julia.phillips@FTIConsulting.com)

#### **Switzerland**

Martin Meier-Pfister, IRF Communications  
+41 43 244 81 40  
[mailto:martin.meier-pfister@irfcom.ch](mailto:mailto:martin.meier-pfister@irfcom.ch)

#### **Germany/Europe**

Anne Hennecke, MC Services  
+49 211 52925222  
[anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu)

#### **USA**

Beth Kurth, LaVoieHealthScience  
+1 617 374 8800, Ext. 106  
[bkurth@lavoiehealthscience.com](mailto:bkurth@lavoiehealthscience.com)